Reference number : GC-2017-Q4-00330, amendment number : , agreement type : G, recipient legal name : Chen, Pu (University of Waterloo), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Graphene-based nanomaterials have expanded their applications to biomedicine, ranging from biosensors and_x000D_
imaging to scaffolds for tissue engineering to drug and gene delivery in cancer treatment. In particular,_x000D_
graphene oxide derivatives (GODs) are the main focus of the intensive research in the field of drug/gene_x000D_
delivery, due to their oxygen functionalities that make them soluble in aqueous biological media. GODs can_x000D_
interact with biological molecules through both covalent and non-covalent bonds that opens up more_x000D_
opportunities in for targeted drug delivery. Specific targeting, efficient drug release and intracellular trafficking_x000D_
are the most important requirements in a drug delivery system. The GOD delivery performance has yet to be_x000D_
optimized to meet all these requirements. On the other hand, peptides are an important class of biomaterial_x000D_
building blocks, providing unique bio-functions such as targeting, antimicrobial activity, cell penetration, and_x000D_
immunotherapy. Here, we propose to explore the possibility of peptide functionalized GODs in drug and gene_x000D_
delivery, in terms of their functional versatility and tunability. The team, consisting of University of Waterloo_x000D_
researchers and their industry partner, Zerocor, will first try to understand the interaction between peptide and_x000D_
GOD, and the competition among different peptides and therapeutic drugs on GOD binding. This part of study_x000D_
will provide information on how to construct GOD-based drug carriers that functionalize with different types_x000D_
of peptides. The physicochemical properties of the GOD-peptide/drug complexes will be investigated and_x000D_
characterized using a variety of techniques, to reveal cellular uptake mechanisms and cell membrane_x000D_
interactions. The team will subsequently study the functions of a selected number of drug-peptide-GOD_x000D_
complexes, in terms of tumor cell targeting, lysosomal escape and triggered drug/cargo release. Optimized_x000D_
formulations of GOD/peptide/drug complexes will be tested for their stability in physiologically relevant_x000D_
solutions by means of size distribution, assembly morphology, drug loading and efficacy. Eventually, the_x000D_
multifunctional GOD-based drug delivery system is expected to be obtained for future in vivo tests., program purpose french : Graphene-based nanomaterials have expanded their applications to biomedicine, ranging from biosensors and_x000D_
imaging to scaffolds for tissue engineering to drug and gene delivery in cancer treatment. In particular,_x000D_
graphene oxide derivatives (GODs) are the main focus of the intensive research in the field of drug/gene_x000D_
delivery, due to their oxygen functionalities that make them soluble in aqueous biological media. GODs can_x000D_
interact with biological molecules through both covalent and non-covalent bonds that opens up more_x000D_
opportunities in for targeted drug delivery. Specific targeting, efficient drug release and intracellular trafficking_x000D_
are the most important requirements in a drug delivery system. The GOD delivery performance has yet to be_x000D_
optimized to meet all these requirements. On the other hand, peptides are an important class of biomaterial_x000D_
building blocks, providing unique bio-functions such as targeting, antimicrobial activity, cell penetration, and_x000D_
immunotherapy. Here, we propose to explore the possibility of peptide functionalized GODs in drug and gene_x000D_
delivery, in terms of their functional versatility and tunability. The team, consisting of University of Waterloo_x000D_
researchers and their industry partner, Zerocor, will first try to understand the interaction between peptide and_x000D_
GOD, and the competition among different peptides and therapeutic drugs on GOD binding. This part of study_x000D_
will provide information on how to construct GOD-based drug carriers that functionalize with different types_x000D_
of peptides. The physicochemical properties of the GOD-peptide/drug complexes will be investigated and_x000D_
characterized using a variety of techniques, to reveal cellular uptake mechanisms and cell membrane_x000D_
interactions. The team will subsequently study the functions of a selected number of drug-peptide-GOD_x000D_
complexes, in terms of tumor cell targeting, lysosomal escape and triggered drug/cargo release. Optimized_x000D_
formulations of GOD/peptide/drug complexes will be tested for their stability in physiologically relevant_x000D_
solutions by means of size distribution, assembly morphology, drug loading and efficacy. Eventually, the_x000D_
multifunctional GOD-based drug delivery system is expected to be obtained for future in vivo tests., agreement title english : Peptide functionalized graphene oxide derivatives for drug and gene delivery, agreement title french : Peptide functionalized graphene oxide derivatives for drug and gene delivery, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-02-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada